MEDICAL UPDATE: Alpha Interferon in Combination With AZT And ddC

MEDICAL UPDATE: Alpha Interferon in Combination With AZT And ddC

Being Alive Newsletter, Being Alive/Los Angeles - October 1992
Mark Katz MD and reported by Jim Stoecker

Burroughs-Wellcome, manufacturer of AZT and a form of alpha interferon, is sponsoring a 76 week study in eight cities throughout the US (the study site closest to Los Angeles is San Francisco). This study will compare the efficacy of the combination of AZT and ddC to that of the combination of AZT, ddC and alpha interferon.

The study participants will be in the 300-500 T-cell range. Researchers are looking to raise average T-cell count to the 800 range.

What makes this study a landmark is the inclusion of a drug that is not an RT inhibitor. Alpha interferon is believed to interfere in the HIV life cycle at a point different from that of AZT, ddC or ddI. This has the potential of providing a more potent combination antiviral therapy than we currently have with just the RT inhibitors.
921001
BA921006

AEGiS is made possible through unrestricted grants from Roxane Laboratories, the National Library of Medicine, and donations from users like you. Always watch for outdated information. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

Copyright © 1992 - Beings Alive. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. Being Alive, 621 N. San Vicente Blvd., West Hollywood, CA 90069, Tel - 310.289.2551; FAX - 310.289.9866; Email: BeiAlive@aol.com http://www.beingalivela.org/

This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1992. AEGIS.